SENATE BILL 908

C3

0lr3347 CF 0lr1718

By: **Senator Stone** Introduced and read first time: February 16, 2010 Assigned to: Rules

A BILL ENTITLED

1 AN ACT concerning

2 Health Insurance – Coverage for the Treatment of Bleeding Disorders

3 FOR the purpose of requiring certain insurers, nonprofit health service plans, and health maintenance organizations to provide coverage for certain pharmacy 4 $\mathbf{5}$ care, home nursing services, treatment at a hemophilia treatment center, and 6 clinical laboratory services that an insured's or enrollee's treating physician 7 determines are necessary to prevent, diagnose, or treat a bleeding disorder; 8 requiring the insurers, nonprofit health service plans, and health maintenance 9 organizations to provide coverage for certain blood clotting products and to 10 preapprove or preauthorize a prescription for a blood clotting product in a certain manner, under certain circumstances; requiring the insurers, nonprofit 11 12health service plans, and health maintenance organizations to provide to an 13insured or enrollee a choice of a certain number of certain full-service home 14 care providers; authorizing the imposition of a copayment or coinsurance 15requirement or deductible for certain coverage under certain circumstances; defining certain terms; providing for the application of this Act; and generally 1617 relating to coverage for bleeding disorders under health insurance policies and 18 contracts.

- 19 BY adding to
- 20 Article Health General
- 21 Section 19–706(cccc)
- 22 Annotated Code of Maryland
- 23 (2009 Replacement Volume)
- 24 BY adding to
- 25 Article Insurance
- 26 Section 15–845
- 27 Annotated Code of Maryland
- 28 (2006 Replacement Volume and 2009 Supplement)

EXPLANATION: CAPITALS INDICATE MATTER ADDED TO EXISTING LAW. [Brackets] indicate matter deleted from existing law.




	2 SENATE BILL 908
1	Preamble
$2 \\ 3$	WHEREAS, Hemophilia is a rare, hereditary bleeding disorder that affects hundreds of residents of the State; and
4	WHEREAS, Hemophilia is a chronic, lifelong, and incurable disease; and
$5\\6\\7$	WHEREAS, Until the 1970s, individuals afflicted with severe hemophilia suffered from uncontrollable internal bleeding, crippling orthopedic deformities, and a diminished lifespan; and
8 9 10	WHEREAS, The scientific discovery of highly purified blood clotting factors has enabled many individuals with hemophilia and other bleeding disorders to lead normal lives free of pain and crippling arthritis; and
11 12 13	WHEREAS, The blood clotting factors are expensive and must be injected intravenously several times a week, but this medicine can be administered in an individual's home, which is the preferred method of treatment; and
$\begin{array}{c} 14 \\ 15 \end{array}$	WHEREAS, In addition to blood clotting factors, individuals with hemophilia require expert, specialized medical care at regional hemophilia treatment centers; and
16 17 18 19	WHEREAS, Individuals with hemophilia and other bleeding disorders need access to health insurance coverage for blood clotting products, medical care, home health services, and laboratory services necessary to enable them to lead healthy, productive lives; now, therefore,
$\begin{array}{c} 20\\ 21 \end{array}$	SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND, That the Laws of Maryland read as follows:
22	Article – Health – General
23	19–706.
$\frac{24}{25}$	(CCCC) THE PROVISIONS OF § 15–845 OF THE INSURANCE ARTICLE APPLY TO HEALTH MAINTENANCE ORGANIZATIONS.
26	Article – Insurance
27	15-845.
$28 \\ 29$	(A) (1) IN THIS SECTION THE FOLLOWING WORDS HAVE THE MEANINGS INDICATED.
30 31 32	(2) (I) "ANCILLARY INFUSION EQUIPMENT AND SUPPLIES" MEANS THE EQUIPMENT AND SUPPLIES REQUIRED TO INFUSE A BLOOD CLOTTING PRODUCT INTO A HUMAN VEIN.

1 (II) "ANCILLARY INFUSION EQUIPMENT AND SUPPLIES" 2 INCLUDES SYRINGES, NEEDLES, STERILE GAUZE, ALCOHOL SWABS, 3 TOURNIQUETS, MEDICAL TAPE, SHARPS OR EQUIVALENT BIOHAZARD WASTE 4 CONTAINERS FOR THE REMOVAL AND DISPOSAL OF HAZARDOUS WASTE, AND 5 COLD COMPRESSION PACKS.

6 (3) (I) "BLEEDING DISORDER" MEANS A MEDICAL CONDITION 7 THAT IS CHARACTERIZED BY A SEVERE DEFICIENCY OR ABSENCE OF ONE OR 8 MORE ESSENTIAL BLOOD CLOTTING PROTEINS IN THE HUMAN BLOOD, OFTEN 9 REFERRED TO AS FACTORS.

"BLEEDING DISORDER" INCLUDES: 10 **(II)** 11 1. ALL FORMS OF HEMOPHILIA; 122. **VON WILLEBRAND DISEASE; AND** 133. ANY OTHER BLEEDING DISORDER THAT RESULTS 14IN UNCONTROLLABLE BLEEDING OR ABNORMAL BLOOD CLOTTING. (4) "BLOOD 15**(I)** CLOTTING PRODUCT" MEANS AN 16 INTRAVENOUSLY ADMINISTERED MEDICINE THAT IS: 171. MANUFACTURED FROM HUMAN PLASMA OR **RECOMBINANT BIOTECHNOLOGY TECHNIQUES;** 18 19 2. APPROVED FOR DISTRIBUTION BY THE FDA; AND 203. USED FOR THE TREATMENT AND PREVENTION OF 21SYMPTOMS ASSOCIATED WITH BLEEDING DISORDERS. 22**"BLOOD CLOTTING PRODUCT" INCLUDES: (II)** 231. FACTOR VIIA, FACTOR VIII, AND FACTOR IX 24**PRODUCTS;** 2. 25**VON WILLEBRAND FACTOR PRODUCTS;** 3. 26**PROTHROMBIN COMPLEX CONCENTRATES;** 27**4**. ACTIVATED PROTHROMBIN COMPLEX 28**CONCENTRATES; AND**

	4 SENATE BILL 908
$\frac{1}{2}$	5. ANY OTHER PRODUCT APPROVED BY THE FDA FOR THE TREATMENT OF BLEEDING DISORDERS AND ASSOCIATED INHIBITORS.
$\frac{3}{4}$	(5) (I) "CLINICAL LABORATORY SERVICES" MEANS SERVICES THAT ARE:
$5 \\ 6$	1. PROVIDED AT A CLINICAL COAGULATION LABORATORY LOCATED AT A HEMOPHILIA TREATMENT CENTER; AND
7 8 9 10 11	2. DETERMINED BY AN INSURED'S OR ENROLLEE'S TREATING PHYSICIAN TO BE MEDICALLY NECESSARY, INCLUDING CIRCUMSTANCES DEEMED URGENT BY THE TREATING PHYSICIAN, FOR THE SCREENING, DIAGNOSIS, PROVISIONAL DIAGNOSIS, OR TREATMENT OF A BLEEDING DISORDER OR SUSPECTED BLEEDING DISORDER.
$12 \\ 13 \\ 14 \\ 15$	(II) "CLINICAL LABORATORY SERVICES" INCLUDES SCREENING FOR VON WILLEBRAND DISEASE OR OTHER BLEEDING DISORDER CONDUCTED BEFORE AN INSURED OR ENROLLEE UNDERGOES ANY INVASIVE UTERINE SURGICAL PROCEDURE FOR THE TREATMENT OF MENORRHAGIA.
16	(6) "FDA" MEANS THE U.S. FOOD AND DRUG ADMINISTRATION.
17 18 19 20 21	(7) "Full-service home care provider" means a person that sells or provides blood clotting products, ancillary infusion equipment and supplies, home nursing services, and assistance to an individual for the management of bleeding disorders in a home setting.
$22 \\ 23 \\ 24$	(8) "HEMOPHILIA" MEANS A HUMAN BLEEDING DISORDER CAUSED BY A HEREDITARY DEFICIENCY OF THE FACTOR VIII, FACTOR IX, OR FACTOR XI BLOOD CLOTTING PROTEIN IN HUMAN BLOOD.
$\frac{25}{26}$	(9) "HEMOPHILIA TREATMENT CENTER" MEANS A FEDERALLY FUNDED ENTITY THAT:
27 28	(I) SPECIALIZES IN TREATING PATIENTS WITH BLEEDING DISORDERS; AND
29 30 31	(II) HAS AT LEAST A HEMATOLOGIST, A NURSE, A SOCIAL WORKER, AND A PHYSICAL THERAPIST WORKING AS A TEAM TO DELIVER COMPREHENSIVE CARE TO PATIENTS AND FAMILIES.



(10) "HOME NURSING SERVICES" MEANS SPECIALIZED NURSING 1 $\mathbf{2}$ CARE PROVIDED IN AN INDIVIDUAL'S HOME TO ASSIST THE INDIVIDUAL IN THE 3 **RECONSTITUTION AND ADMINISTRATION OF BLOOD CLOTTING PRODUCTS.** 4 (11) "PHARMACY CARE" MEANS A BLOOD CLOTTING PRODUCT OR $\mathbf{5}$ ANCILLARY INFUSION EQUIPMENT AND SUPPLIES THAT IS: 6 **(I)** PRESCRIBED BY A LICENSED PHYSICIAN; AND $\overline{7}$ **(II)** USED IN THE TREATMENT OF A BLEEDING DISORDER. 8 (12) "VON WILLEBRAND DISEASE" MEANS A BLEEDING DISORDER 9 CAUSED BY A HEREDITARY DEFICIENCY OR ABNORMALITY OF THE VON WILLEBRAND FACTOR IN HUMAN BLOOD. 10 11 **(**B**)** THIS SECTION APPLIES TO: 12(1) INSURERS AND NONPROFIT HEALTH SERVICE PLANS THAT 13PROVIDE HOSPITAL, MEDICAL, OR SURGICAL BENEFITS TO INDIVIDUALS OR 14GROUPS ON AN EXPENSE-INCURRED BASIS UNDER HEALTH INSURANCE 15POLICIES THAT ARE ISSUED OR DELIVERED IN THE STATE; AND 16 (2) HEALTH MAINTENANCE ORGANIZATIONS THAT PROVIDE 17HOSPITAL, MEDICAL, OR SURGICAL BENEFITS TO INDIVIDUALS OR GROUPS 18 UNDER CONTRACTS THAT ARE ISSUED OR DELIVERED IN THE STATE. 19(C) AN ENTITY SUBJECT TO THIS SECTION SHALL PROVIDE COVERAGE 20FOR ALL MEDICALLY NECESSARY AND APPROPRIATE PHARMACY CARE, HOME 21NURSING SERVICES, TREATMENT AT A HEMOPHILIA TREATMENT CENTER, AND 22CLINICAL LABORATORY SERVICES THAT AN INSURED'S OR ENROLLEE'S 23TREATING PHYSICIAN DETERMINES ARE NECESSARY TO PREVENT, DIAGNOSE, 24OR TREAT A BLEEDING DISORDER. 25(D) (1) AN ENTITY SUBJECT TO THIS SECTION: 26SHALL PROVIDE COVERAGE FOR THE BLOOD CLOTTING **(I)** 27PRODUCT PRESCRIBED BY THE TREATING PHYSICIAN OF AN INSURED OR 28**ENROLLEE; AND** 29MAY NOT REQUIRE AN INSURED OR ENROLLEE TO USE A (II) SUBSTITUTE BLOOD CLOTTING PRODUCT WITHOUT PRIOR APPROVAL OF THE 30 INSURED'S OR ENROLLEE'S TREATING PHYSICIAN. 31

1 (2) IF AN ENTITY SUBJECT TO THIS SECTION REQUIRES 2 PREAPPROVAL OR PREAUTHORIZATION OF A PRESCRIPTION FOR A BLOOD 3 CLOTTING PRODUCT BEFORE IT IS DISPENSED, THE ENTITY SHALL COMPLETE 4 PREAPPROVAL OR PREAUTHORIZATION WITHIN THE LATER OF 24 HOURS OR 1 5 BUSINESS DAY.

6 (3) AN ENTITY SUBJECT TO THIS SECTION SHALL PROVIDE 7 COVERAGE FOR:

8 **(I)** FDA–APPROVED BRANDS OF BLOOD **CLOTTING** 9 PRODUCTS IN MULTIPLE ASSAY RANGES, LOW, MEDIUM, AND HIGH, AS 10 APPLICABLE, INCLUDING BLOOD CLOTTING PRODUCTS MANUFACTURED FROM 11 HUMAN PLASMA AND THOSE MANUFACTURED WITH RECOMBINANT 12**BIOTECHNOLOGY TECHNIQUES; AND**

(II) BLOOD CLOTTING PRODUCTS AS PRESCRIBED BY THE
 INSURED'S OR ENROLLEE'S TREATING PHYSICIAN FOR INPATIENT CARE,
 OUTPATIENT CARE, AND HOME TREATMENT OF BLEEDING DISORDERS.

16 (4) IF AN ENTITY SUBJECT TO THIS SECTION HAS A DRUG 17 FORMULARY, INCLUDING A DRUG FORMULARY RELATING TO SPECIALTY 18 PHARMACEUTICAL THERAPIES, ALL FDA-APPROVED BLOOD CLOTTING 19 PRODUCTS SHALL BE INCLUDED IN THE FORMULARY.

20 (E) AN ENTITY SUBJECT TO THIS SECTION SHALL PROVIDE TO AN 21 INSURED OR ENROLLEE A CHOICE OF AT LEAST THREE FULL-SERVICE HOME 22 CARE PROVIDERS THAT:

(1) SUPPLY BLOOD CLOTTING PRODUCTS AND HOME NURSING
SERVICES AS PRESCRIBED BY THE INSURED'S OR ENROLLEE'S TREATING
PHYSICIAN, WITHOUT SUBSTITUTION OF A BLOOD CLOTTING PRODUCT UNLESS
APPROVED IN ADVANCE BY THE TREATING PHYSICIAN;

27SUPPLY ALL FDA-APPROVED BRANDS OF BLOOD CLOTTING (2) PRODUCTS IN MULTIPLE ASSAY RANGES, LOW, MEDIUM, AND HIGH, AS 2829APPLICABLE, INCLUDING BLOOD CLOTTING PRODUCTS MANUFACTURED FROM 30 HUMAN PLASMA AND THOSE MANUFACTURED WITH RECOMBINANT 31**BIOTECHNOLOGY TECHNIQUES;**

32 (3) SUPPLY ALL NECESSARY ANCILLARY INFUSION EQUIPMENT 33 AND SUPPLIES; (4) PROVIDE, DIRECTLY OR THROUGH A RELIABLE THIRD-PARTY,
 HOME NURSING SERVICES THAT ARE PRESCRIBED AND DEEMED NECESSARY BY
 THE INSURED'S OR ENROLLEE'S TREATING PHYSICIAN;

4 **(5)** ON RECEIPT OF A PRESCRIPTION, SEND WITHIN **3** BUSINESS 5 DAYS AND IN A SINGLE SHIPMENT, THE PRESCRIBED BLOOD CLOTTING 6 PRODUCT AND ANCILLARY INFUSION EQUIPMENT AND SUPPLIES TO THE 7 INSURED OR ENROLLEE;

8 (6) PROVIDE A PHARMACIST ON CALL, 24 HOURS A DAY, 7 DAYS A
9 WEEK, TO FILL A PRESCRIPTION FOR A BLOOD CLOTTING PRODUCT;

10 (7) IF AN INSURED OR ENROLLEE NEEDS A BLOOD CLOTTING 11 PRODUCT ON AN EMERGENCY BASIS, IMMEDIATELY NOTIFY THE INSURED'S OR 12 ENROLLEE'S TREATING PHYSICIAN AND, IN CONSULTATION WITH THE TREATING 13 PHYSICIAN, ENSURE ACCESS TO THE BLOOD CLOTTING PRODUCT AS SOON AS 14 PRACTICABLE, AND IN NO EVENT MORE THAN 12 HOURS AFTER NOTICE OF THE 15 EMERGENCY SITUATION;

16 (8) NOTIFY THE INSURED OR ENROLLEE, AS SOON AS
17 PRACTICABLE, OF ANY RECALL OR WITHDRAWAL OF A BLOOD CLOTTING
18 PRODUCT OR ANCILLARY INFUSION EQUIPMENT AND SUPPLIES; AND

19(9)PROVIDE SHARPS CONTAINERS OR THE EQUIVALENT FOR THE20REMOVAL AND DISPOSAL OF MEDICAL WASTE.

(F) (1) SUBJECT TO PARAGRAPH (2) OF THIS SUBSECTION, THE
 COVERAGE REQUIRED UNDER THIS SECTION MAY BE SUBJECT TO A COPAYMENT
 OR COINSURANCE REQUIREMENT OR DEDUCTIBLE THAT AN ENTITY SUBJECT TO
 THIS SECTION IMPOSES FOR SIMILAR COVERAGES UNDER THE SAME HEALTH
 INSURANCE POLICY OR CONTRACT.

(2) THE COPAYMENT OR COINSURANCE REQUIREMENT OR
DEDUCTIBLE IMPOSED UNDER PARAGRAPH (1) OF THIS SUBSECTION MAY NOT
BE GREATER THAN THE COPAYMENT OR COINSURANCE REQUIREMENT OR
DEDUCTIBLE IMPOSED BY THE ENTITY FOR SIMILAR COVERAGES.

30 SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall apply to 31 all health insurance policies and contracts issued, delivered, or renewed in the State 32 on or after October 1, 2010.

33 SECTION 3. AND BE IT FURTHER ENACTED, That this Act shall take effect
 34 October 1, 2010.